双顺反子抗 CD19/CD20 CAR 构建体的开发,包括消除非预期核酸序列缺失
Development of a bicistronic anti-CD19/CD20 CAR construct including abrogation of unexpected nucleic acid sequence deletions.
16.0分
★☆☆☆☆
站内排序·非疗效
FRONTIER PAPERS
MEMBER ACCOUNT
登录成功会直接打开下一页。